Last reviewed · How we verify
NCT06355908: ENHANCING
IL13Rα2 CAR-T for Patients With r/r Glioma
Phase 1 trial testing IL13Rα2 CAR-T in Glioma in 30 participants. Suspended.
1 May 2026
Quick facts
| Lead sponsor | Yang Zhang |
|---|---|
| Phase | Phase 1 |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 21 March 2024 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 May 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- IL13Rα2 CAR-T — full drug profile →
Conditions studied
- Glioma — all drugs for Glioma →
Sponsor
Yang Zhang — full company profile →
Who can join
Adults 18 to 75, any sex, with Glioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a dose exploration clinical trial to assess the safety and feasibility of the IL13Ra2-targeted CAR-T in glioma.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Therapeutic approaches to modulate the immune microenvironment in gliomas.
Sarantopoulos A, Ene C, Aquilanti E. · · 2024 · cited 19× · PMID 39443641 · DOI 10.1038/s41698-024-00717-4 -
Advances in CAR-T therapy for central nervous system tumors.
Zhou D, Zhu X, Xiao Y. · · 2024 · cited 15× · PMID 39506843 · DOI 10.1186/s40364-024-00679-6 -
Trends in the immunotherapy for glioblastoma: A two-decade bibliometric analysis.
Long Z, Yi Z, Yan W, Wang H. · · 2025 · cited 3× · PMID 39950580 · DOI 10.1080/21645515.2025.2466299 -
Optic Pathway Glioma: Current Treatment Approaches and Ongoing Clinical Trials.
Elzaafarany O, Elhomosany S, Rincones A, Dlugi V, et al · · 2025 · cited 2× · PMID 40867225 · DOI 10.3390/brainsci15080894 -
Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers.
Sabnis NA, Cooksey LC, Jayakumar H, Moguel Mendez M, et al · · 2026 · PMID 42192798 · DOI 10.3390/brainsci16050487 -
Astrocytes in neuroinflammation and brain cancer.
Sun W, Chen P, Xu XY, Zhang JQ, et al · · 2026 · PMID 41910655 · DOI 10.1186/s43556-026-00439-y -
Loss of IL13RA2 promotes metastatic tumor growth in triple-negative breast cancer via increased AKT and NF-κB signaling.
Bindeman WE, Corn KC, Rafat M, Fingleton B. · · 2025 · PMID 40663259 · DOI 10.1007/s10585-025-10362-1
Verify or expand the search:
- PubMed search for NCT06355908
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glioma
Currently open trials in the same condition.
- NCT07486713 — Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · Phase 4 · recruiting
- NCT07236840 — Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors · recruiting
- NCT07450872 — Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors · recruiting
- NCT07405372 — Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas · recruiting
- NCT07338539 — BIO-SHORT: Biologically Guided Short-Course Hypofractionated RT for Poor-Prognosis GBM · Phase 2 · recruiting
Other Yang Zhang trials
Trials by the same sponsor.
- NCT07119177 — Long-term Evaluation of Gestational Endocrine & Metabolic Dynamics · recruiting
- NCT06653907 — Levothyroxine Intervention in Pregnant Women with TSH （2.5 MIU/L-upper Limit of Reference Range） and Negative Thyroid Pe · Phase 4 · not yet recruiting
- NCT04749641 — Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06355908 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yang Zhang
- Last refreshed: 20 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06355908.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing